Cargando…

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

PURPOSE: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the phase II PIVOT-02 trial. PIVOT IO 001 (ClinicalTrials.gov identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diab, Adi, Gogas, Helen, Sandhu, Shahneen, Long, Georgina V., Ascierto, Paolo A., Larkin, James, Sznol, Mario, Franke, Fabio, Ciuleanu, Tudor E., Pereira, Caio, Muñoz Couselo, Eva, Bronzon Damian, Fernanda, Schenker, Michael, Perfetti, Aldo, Lebbe, Celeste, Quéreux, Gaëlle, Meier, Friedegund, Curti, Brendan D., Rojas, Carlos, Arriaga, Yull, Yang, Haisu, Zhou, Ming, Ravimohan, Shruthi, Statkevich, Paul, Tagliaferri, Mary A., Khushalani, Nikhil I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602507/ https://www.ncbi.nlm.nih.gov/pubmed/37651676 http://dx.doi.org/10.1200/JCO.23.00172

Ejemplares similares

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
por: Tannir, Nizar M, et al.
Publicado: (2022)

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
por: Sharma, Meenu, et al.
Publicado: (2020)

Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
por: Anastasopoulou, Amalia, et al.
Publicado: (2022)

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
por: D’Angelo, Sandra P., et al.
Publicado: (2022)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
por: Hennessy, Marlene, et al.
Publicado: (2020)

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
por: Veatch, Joshua R, et al.
Publicado: (2020)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014)

Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer
por: Bates, Amber M., et al.
Publicado: (2021)

Melanoma: A model for testing new agents in combination therapies
por: Ascierto, Paolo A, et al.
Publicado: (2010)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Tuberculosis and lung damage: from epidemiology to pathophysiology
por: Ravimohan, Shruthi, et al.
Publicado: (2018)

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT
por: Rolig, Annah S, et al.
Publicado: (2022)

Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
por: Walker, John W, et al.
Publicado: (2020)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Histological Regression of Giant Cell Tumor of Bone Following RANK Ligand Inhibition
por: Dietrich, Martin F., et al.
Publicado: (2014)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Early Emergence and Selection of a SIV-LTR C/EBP Site Variant in SIV-Infected Macaques That Increases Virus Infectivity
por: Ravimohan, Shruthi, et al.
Publicado: (2012)

Correction: Early Emergence and Selection of a SIV-LTR C/EBP Site Variant in SIV-Infected Macaques That Increases Virus Infectivity
por: Ravimohan, Shruthi, et al.
Publicado: (2013)

Common Variation in NLRP3 Is Associated With Early Death and Elevated Inflammasome Biomarkers Among Advanced HIV/TB Co-infected Patients in Botswana
por: Ravimohan, Shruthi, et al.
Publicado: (2018)

A Narrative Review of Emerging Therapeutics for COVID-19
por: Willis, Van C., et al.
Publicado: (2020)

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

The weather of Los Angeles, 1998-2002
por: Khushalani, Bharat
Publicado: (2002)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review
por: Ziogas, Dimitrios C., et al.
Publicado: (2021)

Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al
por: Weber, Jeffrey, et al.
Publicado: (2022)

Matrix Metalloproteinases in Tuberculosis-Immune Reconstitution Inflammatory Syndrome and Impaired Lung Function Among Advanced HIV/TB Co-infected Patients Initiating Antiretroviral Therapy
por: Ravimohan, Shruthi, et al.
Publicado: (2015)

Impact of hydronephrosis and kidney function on survival in newly diagnosed advanced cervical cancer
por: Damian, Fernanda Bronzon, et al.
Publicado: (2022)

Variations in breast cancer surgical treatment and timing: determinants and disparities
por: Dankwa-Mullan, Irene, et al.
Publicado: (2021)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Is acne vulgaris exacerbated during the military conflict in Ukraine? A self-reported cross-sectional prospective study
por: Szepietowski, Jacek C., et al.
Publicado: (2023)

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
por: Vinnard, Christopher, et al.
Publicado: (2017)

Somatic Mutations Profile of a Young Patient With Metastatic Urothelial Carcinoma Reveals Mutations in Genes Involved in Ion Channels
por: Sharma, Jyoti, et al.
Publicado: (2019)

Rapid review: Identification of digital health interventions in atherosclerotic-related cardiovascular disease populations to address racial, ethnic, and socioeconomic health disparities
por: Thomas Craig, Kelly J., et al.
Publicado: (2020)

BRAF and beyond: Tailoring strategies for the individual melanoma patient
por: Jarkowski, Anthony, et al.
Publicado: (2014)

Does Assisted Living Capacity Influence Case Mix at Nursing Homes?
por: Clement, Jan P., et al.
Publicado: (2015)

Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications
por: Sznol, Mario, et al.
Publicado: (2023)

Catheter-Related Acremonium kiliense Fungemia in a Patient with Ulcerative Colitis under Treatment with Infliximab
por: Díaz-Couselo, Fernando A., et al.
Publicado: (2011)

Complete chloroplast genome of Dactylicapnos torulosa (Hook. & Thoms.) Hutch., a medicinal plant from southwest China and its phylogeny
por: Hu, Haisu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mbp6jao0in5i7sn3pnekgc7cct